SMN1 and frontotemporal dementia: Gene therapies have already been successfully implemented for spinal muscular atrophy (SMA1), and therapies for other neurodegenerative diseases, including AD, PD, ALS, FTD, and Huntington’s disease (HD), are currently under development [185,186].